Premium
Treatment of transfusion‐dependent congenital dyserythropoietic anemia Type I patients with pegylated interferon alpha‐2a
Author(s) -
AbuQuider Abed,
Asleh Mahdi,
Shalev Hanna,
Fruchtman Yariv,
BenHarosh Meriam,
Beck Guy,
Kapelushnik Josef
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13428
Subject(s) - medicine , anemia , gastroenterology , pegylated interferon , hemoglobin , complete response , alpha interferon , ferritin , interferon , surgery , immunology , chemotherapy , ribavirin , chronic hepatitis , virus
Objective Pegylated IFN‐α2a has been reported in two case reports as being efficacious in treating CDA‐I patients. This study aims to assess its efficacy on a series of CDA‐I patients. Methods Study sample consisted of seven CDA type 1 transfusion‐dependent patients. They received pegylated interferon alpha‐2a at an initial dose of 90‐180 µg once a week, tapered according to clinical response and side effects. Good response was defined as Hb ≥ 10 g/dL for ≥3 months, partial response was defined as 7 ≤ Hb<10 g/dL for ≥3 months, and no response was defined as HB < 7 g/dL for over 3 months on treatment. Time to response was defined as the time needed to achieve hemoglobin levels ≥ 10 g/dL without transfusion. Patients were evaluated periodically by abdominal ultrasounds to rule out liver adenomas. Results Five patients (71%) had a good response to treatment. One patient stopped treatment due to side effects. One patient had partial response. One patient, with more severe phenotype and poor compliance, had poor response to treatment. No abnormal findings were found in ultrasound examination. No effect on serum ferritin level could be established. Conclusion Pegylated interferon α2a therapy is efficacious in CDA‐I patients with a reasonable safety profile.